Skip to main content
Premium Trial:

Request an Annual Quote

Paradigm Genetics, on Notice from Nasdaq, Plans to Appeal Decision

NEW YORK, Jan. 29-Joining the small crowd of genomics firms that are on the verge of losing a spot on the trading floor, Paradigm Genetics said today that Nasdaq notified the company on Jan. 24 that it is now subject to delisting.

 

Paradigm's stock has been trading below the benchmark $1 minimum bid price since Oct. 1. By Nasdaq rules, if a company is priced under that cutoff for more than 30 consecutive trading days, it has 90 days to boost its stock price or risk being evicted from the exchange.

 

The company plans to appeal the determination, and its stock will continue to be traded on the exchange pending that decision.

 

Paradigm Genetics is also considering a transfer to Nasdaq's small cap market, which would give the company more time to hike its share price back above the $1 limit.

 

Earlier this month, the company said it was selling off its ParaGencrop science division to a Canadian crop shop in a deal expected to close by mid-February.

 

Other firms on the Nasdaq warning list include Deltagen, Lynx Therapeutics, and Orchid Biosciences.

 

 

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.